Lifecore continues to work towards the installation and qualification of its high-speed multi-purpose 5-head and 10-head isolator fillers and currently estimates that its theoretical annual aseptic production capacity would increase to approximately 70 million units in fiscal year 2027, which is more than triple the Company’s current theoretical capacity of 22 million units. The current estimates for theoretical capacity have resulted from extensive factory acceptance testing associated with the new isolator fillers, including evaluating filling speeds and volumes, modeling the types of product formulations under evaluation with our pipeline. The Company currently expects its 5-head filler to be GMP ready in August 2024. Lifecore’s Hyaluronic Acid supply agreement with Alcon also continues to advance with progress on transitioning to a 24/7 labor force. The Company has already increased HA capacity by 38% since the beginning of fiscal year 2024 and currently anticipates further increases through yield improvements of approximately 20% during fiscal year 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFCR:
- LFCR Upcoming Earnings Report: What to Expect?
- Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update
- Lifecore Biomedical Announces New CEO and Equity Inducement Plan
- Lifecore concludes strategic review, announces management, board changes
- Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes